Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NextCure Inc
NXTC | US
10.52
USD-1.88
-15.16%
NXTC | US
Loading StockChartView...
About NextCure Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
10.52
Open
11.61
High
11.80
Low
9.90
NextCure Inc. a clinical-stage biopharmaceutical company engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410 an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762 a monoclonal antibody that binds specifically to B7-H4 a protein expressed on multiple tumor types; and NC525 a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure Inc. was incorporated in 2015 and is headquartered in Beltsville Maryland.
View LessNXTC | US
Risk
103.2
Sharpe
0.98
Luna's Score
46/100
Recommendation
Hold
Luna says (NXTC | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
142.5%1 month
103.2%3 months
84.0%6 months
99.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.45
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
0.51
Ent. to rev.
1.62
PEG
-
Other Fundamentals
EBITDA
-60.40M
MarketCap
294.31M
MarketCap(USD)
294.31M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-54.75
Short ratio
1.87
Short perc.
0.29
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
3.60
Range1M
4.68
Range3M
5.83
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.92
Price X volume
1.44M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.51 | 0.53 | Par |
| Ent. to Revenue | 1.62 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.45 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 84.04 | 72.80 | Par |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 294.31M | 3.66B | Emerging |
